Cerus reaffirms $229M-$231M 2026 product revenue as it now expects CE Mark clearance in late 2027 (NASDAQ:CERS)

Cerus (CERS) reported Q3 2026 earnings, highlighting 10% year-over-year revenue growth, 12% North American sales increase, and positive adjusted EBITDA for the 10th consecutive quarter. Key achievements include positive Phase III REDeS study results for red blood cell transfusion technology, strong ISC franchise performance, and international INT200 illuminator rollout. The company aims for sustained double-digit growth and financial strength.

Cerus Corp (CERS) reported a 10% revenue increase in Q3 2026, but faced headwinds from geopolitical conflicts and a strong US dollar. Product gross margin declined to 52.4% due to foreign exchange and inflation. Government contract revenue fell to $6.3M. CEO Vivek Jayaraman discussed delays in regulatory approvals, international market challenges, and growth drivers like the BCA agreement. The company expects CE-mark clearance for red blood cell technology in late 2027 and is working on Gen.

Cerus Corporation (CERS) reported positive Phase 3 RedeS trial results for its INTERCEPT Blood System for Red Blood Cells, meeting primary efficacy and safety endpoints. The study showed non-inferiority of INTERCEPT RBCs compared to conventional RBCs, with no significant safety differences. Full results will be submitted for publication and presented at scientific meetings. The FDA has not yet reviewed the final study report.

Cerus reported Q3 EMEA revenue growth of 5%, impacted by geopolitical and currency headwinds. The company's RedeS study met primary efficacy endpoints, with full analysis expected soon. Cerus reaffirmed 2026 revenue guidance of $229M-$231M and reported positive adjusted EBITDA. The company is addressing regulatory questions from the FDA and ANSM. Cerus aims for GAAP profitability and plans to refresh its shelf registration statement.

Cerus Corporation reported a 10% YoY increase in Q3 product revenue, positive adjusted EBITDA for the 10th consecutive quarter, and $3 million in operating cash flow. The company's RedeS met its primary efficacy endpoint, and FY 2026 product revenue guidance was reaffirmed at $229 million–$231 million, according to the company.

Cerus Corp. reported a Q3 loss of $550,000, or less than 1 cent per share, with revenue of $57.7 million. The company expects full-year revenue between $229 million and $231 million.